These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 3217820)
1. Strategies for vaccine development and utilization. Kidson C Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):343-8. PubMed ID: 3217820 [No Abstract] [Full Text] [Related]
3. From vaccine research to manufacture: a guide for the researcher. Allison N; Tranter HS Methods Mol Med; 2003; 87():391-408. PubMed ID: 12958469 [No Abstract] [Full Text] [Related]
4. [Synthetic gene technology for new vaccines]. Mäkelä PH Duodecim; 1988; 104(22):1874-80. PubMed ID: 3065068 [No Abstract] [Full Text] [Related]
5. Design and development of synthetic peptide vaccines: past, present and future. Bijker MS; Melief CJ; Offringa R; van der Burg SH Expert Rev Vaccines; 2007 Aug; 6(4):591-603. PubMed ID: 17669012 [TBL] [Abstract][Full Text] [Related]
6. Strategies for designing and optimizing new generation vaccines. Berzofsky JA; Ahlers JD; Belyakov IM Nat Rev Immunol; 2001 Dec; 1(3):209-19. PubMed ID: 11905830 [TBL] [Abstract][Full Text] [Related]
8. [Current developments in the field of vaccines]. van Eden W; Hensen EJ Tijdschr Diergeneeskd; 1996 Feb; 121(4):108-9. PubMed ID: 8714394 [No Abstract] [Full Text] [Related]
9. Current tuberculosis vaccine development. Young DB Clin Infect Dis; 2000 Jun; 30 Suppl 3():S254-6. PubMed ID: 10875794 [TBL] [Abstract][Full Text] [Related]
10. Methods of delivery to antigen-presenting cells: development of new and improved vaccines. Apostolopoulos V Mol Pharm; 2007; 4(1):1-3. PubMed ID: 17274662 [No Abstract] [Full Text] [Related]
11. The potential role of fowlpox virus in rational vaccine design. Beukema EL; Brown MP; Hayball JD Expert Rev Vaccines; 2006 Aug; 5(4):565-77. PubMed ID: 16989636 [TBL] [Abstract][Full Text] [Related]
12. New tools for antigen delivery to the MHC class I pathway. Morón G; Dadaglio G; Leclerc C Trends Immunol; 2004 Feb; 25(2):92-7. PubMed ID: 15102368 [TBL] [Abstract][Full Text] [Related]
13. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988 [TBL] [Abstract][Full Text] [Related]
14. [The conditions for modern vaccine development]. Murphy FA Zh Mikrobiol Epidemiol Immunobiol; 1990 Nov; (11):83-90. PubMed ID: 2097852 [No Abstract] [Full Text] [Related]
15. Recombinant vaccine development: a novel approach to ectoparasite control. A review of development of a recombinant vaccine for hypodermosis based on hypodermin A. Temeyer KB; Pruett JH; Kuhn I; Files J SAAS Bull Biochem Biotechnol; 1993; 6():31-5. PubMed ID: 7763704 [TBL] [Abstract][Full Text] [Related]
17. Recombinant vectors in vaccine development. The next steps. Ada GL Dev Biol Stand; 1994; 82():251-6. PubMed ID: 7958479 [No Abstract] [Full Text] [Related]
18. New perspectives in vaccine development: mucosal immunity to infections. McGhee JR; Kiyono H Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356 [TBL] [Abstract][Full Text] [Related]
19. The development of malaria vaccines: SPf66--what next? Tanner M; Alonso PL Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632 [TBL] [Abstract][Full Text] [Related]
20. New strategies against an old plague: genetically engineered tuberculosis vaccines. Dreher D; Kok M; Pechère JC; Nicod LP Schweiz Med Wochenschr; 2000 Dec; 130(50):1925-9. PubMed ID: 11189437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]